351 related articles for article (PubMed ID: 28639033)
1. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
2. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
3. Natural Killer Cell Characteristics in Patients With Chronic Hepatitis B Virus (HBV) Infection Are Associated With HBV Surface Antigen Clearance After Combination Treatment With Pegylated Interferon Alfa-2a and Adefovir.
Stelma F; de Niet A; Tempelmans Plat-Sinnige MJ; Jansen L; Takkenberg RB; Reesink HW; Kootstra NA; van Leeuwen EM
J Infect Dis; 2015 Oct; 212(7):1042-51. PubMed ID: 25791117
[TBL] [Abstract][Full Text] [Related]
4. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
[TBL] [Abstract][Full Text] [Related]
5. CD56
Shi A; Zhang X; Xiao F; Zhu L; Yan W; Han M; Luo X; Chen T; Ning Q
J Viral Hepat; 2018 Nov; 25(11):1352-1362. PubMed ID: 29888839
[TBL] [Abstract][Full Text] [Related]
6. Recovery of circulating CD56
Liu N; Liu B; Zhang L; Li H; Chen Z; Luo A; Chen M; Peng M; Yin W; Ren H; Hu P
Int Immunopharmacol; 2018 Sep; 62():59-66. PubMed ID: 29990695
[TBL] [Abstract][Full Text] [Related]
7. Downregulation and altered function of natural killer cells in hepatitis B virus patients treated with entecavir.
Zhao PW; Jia FY; Shan YX; Ji HF; Feng JY; Niu JQ; Ayana DA; Jiang YF
Clin Exp Pharmacol Physiol; 2013 Mar; 40(3):190-6. PubMed ID: 23278368
[TBL] [Abstract][Full Text] [Related]
8. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
9. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels.
Lv GC; Ma WJ; Ying LJ; Jin X; Zheng L; Yang YD
World J Gastroenterol; 2010 Aug; 16(32):4095-9. PubMed ID: 20731026
[TBL] [Abstract][Full Text] [Related]
11. Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy.
Cao W; Lu H; Zhang L; Wang S; Deng W; Jiang T; Lin Y; Yang L; Bi X; Lu Y; Zhang L; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Hu L; Xie Y; Li M
Front Immunol; 2022; 13():1067362. PubMed ID: 36479104
[TBL] [Abstract][Full Text] [Related]
12. Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.
Ghosh S; Nandi M; Pal S; Mukhopadhyay D; Chakraborty BC; Khatun M; Bhowmick D; Mondal RK; Das S; Das K; Ghosh R; Banerjee S; Santra A; Chatterjee M; Chowdhury A; Datta S
Clin Microbiol Infect; 2016 Aug; 22(8):733.e9-733.e19. PubMed ID: 27208430
[TBL] [Abstract][Full Text] [Related]
13. Recovery of NK(CD56+CD3-) Cells after One Year of Tenofovir Therapy for Chronic Hepatitis B Infection.
Lee HH; Kang H; Cho H
J Microbiol Biotechnol; 2017 Jun; 27(6):1204-1308. PubMed ID: 28335588
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between the changes in immune cells and HBeAg loss following antiviral treatment in chronic hepatitis B patients].
Zheng Q; Zhu YY; Chen J; Liu YR; You J; Zeng DW; Lin S; Jiang JJ
Zhonghua Gan Zang Bing Za Zhi; 2012 Nov; 20(11):801-6. PubMed ID: 23206296
[TBL] [Abstract][Full Text] [Related]
15. HBsAg stimulates NKG2D receptor expression on natural killer cells and inhibits hepatitis C virus replication.
Wang XX; Pan XB; Han JC; Cong X; Jin Q; Kong XS; Wei L; Feng B
Hepatobiliary Pancreat Dis Int; 2018 Jun; 17(3):233-240. PubMed ID: 29625837
[TBL] [Abstract][Full Text] [Related]
16. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
[TBL] [Abstract][Full Text] [Related]
17. Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice.
Li F; Wei H; Wei H; Gao Y; Xu L; Yin W; Sun R; Tian Z
Gastroenterology; 2013 Feb; 144(2):392-401. PubMed ID: 23103614
[TBL] [Abstract][Full Text] [Related]
18. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
Ma SW; Huang X; Li YY; Tang LB; Sun XF; Jiang XT; Zhang YX; Sun J; Liu ZH; Abbott WG; Dong YH; Naoumov NV; Hou JL
J Hepatol; 2012 Apr; 56(4):775-81. PubMed ID: 22173154
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
[TBL] [Abstract][Full Text] [Related]
20. An observational study to evaluate the safety and efficacy of telbivudine in adults with chronic hepatitis B.
Sulaiman A; Lesmana LA; Nafrialdi ; Helyanna
Acta Med Indones; 2014 Jan; 46(1):38-43. PubMed ID: 24760807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
